- Citations, last 5 years
- 182
- Works, last 5 years
- 9
- h-index
- 76
- Scientists listed
- 3
- Grants since 2016
- 18
Grants received
2025–2027 · research · R43
Ubiquitin pathway modulators as novel antituberculosis drugs
Kumar Suresh · Progenra (United States) · funded by National Institutes of Health
2024–2026 · research · R43
Ubiquitin pathway modulators for treating pancreatitis
Kumar Suresh · Progenra (United States) · funded by National Institutes of Health
2022–2024 · research · R43
Development of ITCH-activating IRAK4 degraders as dual-targeting drug candidates for the treatment of rheumatoid arthritis
Kumar Suresh · Progenra (United States) · funded by National Institutes of Health
2022–2024 · research · R43
Parkin activators for cardioprotective therapies
Kumar Suresh · Progenra (United States) · funded by National Institutes of Health
2021–2023 · research · R43
Novel TXNIP degraders for treating diabetes
David E Sterner · Progenra (United States) · funded by National Institutes of Health
2020–2022 · research · R43
Targeted protein stabilization using Protein Rescue Targeting Chimeras (PRESTACs)
Kumar Suresh · Progenra (United States) · funded by National Institutes of Health
2019–2021 · research · R43
Ubiquitin E3 ligase activators for treatment of psoriasis
Kumar Suresh · Progenra (United States) · funded by National Institutes of Health
2019–2021 · research · R43
Nonalcoholic Steatohepatitis Therapies from the Ubiquitin Pathway
David E Sterner · Progenra (United States) · funded by National Institutes of Health
2018–2020 · research · R43
Small-molecule inhibition of mechanisms shared across pathogenic cells in systemic lupus erythematosus
Kumar Suresh · Progenra (United States) · funded by National Institutes of Health
2017–2019 · research · R44
Small molecule Parkin activators to treat Alzheimer's Disease
Feng Wang · Progenra (United States) · funded by National Institutes of Health
2017–2018 · research · R44
Ubiquitin pathway inhibitors for treatment of asthma
Kumar Suresh · Progenra (United States) · funded by National Institutes of Health
2017–2019 · research · R43
Small molecule ubiquitin ligase modulators for immunotherapy of cancer
Kumar Suresh · Progenra (United States) · funded by National Institutes of Health
2017–2020 · research · R44
Small molecule Parkin activators to treat Alzheimer's Disease
Kumar Suresh · Progenra (United States) · funded by National Institutes of Health
2017–2019 · research · R44
Ubiquitin pathway inhibitors for treatment of asthma
Kumar Suresh · Progenra (United States) · funded by National Institutes of Health
2016–2018 · research · R43
Novel ubiquitin protease inhibitor for treating asthma
Kumar Suresh · Progenra (United States) · funded by National Institutes of Health
2016–2018 · research · R43
A novel mechanism based therapy for cystic fibrosis
David E Sterner · Progenra (United States) · funded by National Institutes of Health
2016–2018 · research · R43
Small molecule Parkin activators to treat Alzheimer's Disease
Feng Wang · Progenra (United States) · funded by National Institutes of Health
2016–2018 · research · R41
In vitro human model for individualized response to CFTR modulators
Steven Mark Rowe · Progenra (United States) · funded by National Institutes of Health